Across 30 European CTIS rheumatoid arthritis phase 2 & 3 trials, named CRO or specialist vendor support appeared in 12 trials, or 40.0%. CRO use was concentrated in phase 2, where 11 of 22 trials used CRO support, compared with 1 of 8 phase 3 trials. IQVIA / Q² Solutions was the most active named support family, appearing in 6 of 30 trials, followed by ICON / Accellacare in 5, and Parexel and Labcorp in 4 each.
CRO or specialist vendor support was present in 11 of 22 phase 2 trials, or 50.0%, compared with only 1 of 8 phase 3 trials, or 12.5%. CRO-supported trials also accounted for 57 of 91 country-level CTIS entries, or 62.6%, despite representing only 40.0% of trials.
For rheumatoid arthritis, CRO demand is strongest before large confirmatory execution: phase 2 studies generated 91.7% of all CRO-supported trials in the cohort, while phase 3 was more often sponsor- or institution-run in the named CTIS sponsor fields.
IQVIA / Q² Solutions appeared in 6 of 30 trials, or 20.0%, making it the most active named support family. ICON / Accellacare followed with 5 of 30 trials, or 16.7%, while Parexel and Labcorp each appeared in 4 of 30 trials, or 13.3%.
The active support market is not dominated by one CRO. The top five families together appear 22 times across 12 CRO-supported trials, showing that rheumatoid arthritis outsourcing often uses multi-vendor operating models rather than a single full-service CRO only.
CRO demand rose sharply with operational scale. Trials involving 4 or more CTIS countries used CROs in 8 of 10 cases, or 80.0%. Trials enrolling more than 100 participants used CROs in 4 of 6 cases, or 66.7%, while trials with 10 or more sites generated the largest volume of CRO-supported studies: 9 of 15, or 60.0%.
| Capacity band | CRO-supported | Rate |
|---|---|---|
| 4+ countries | 8/10 | 80.0% |
| 4–9 sites | 2/3 | 66.7% |
| >100 participants | 4/6 | 66.7% |
| 10+ sites | 9/15 | 60.0% |
| RA subtype / difficult-to-treat label | 3/5 | 60.0% |
The clearest CRO trigger is EU submission and operating scale: once a rheumatoid arthritis trial crosses into 4 or more CTIS countries, CRO use becomes the default pattern in this dataset. Participant volume also matters, but country footprint is the sharper signal.
Poland, Spain, France, and Germany were the largest site markets. Poland contributed 66 sites and 342 participants across 11 trials, while Spain contributed 65 sites and 207 participants across 16 trials. Germany had the widest trial footprint with 17 trials and 58 sites.
| Country | Sites | Participants | CRO trial rate |
|---|---|---|---|
| Poland | 66 | 342 | 8/11 · 72.7% |
| Spain | 65 | 207 | 10/16 · 62.5% |
| France | 64 | 324 | 4/6 · 66.7% |
| Germany | 58 | 222 | 10/17 · 58.8% |
| Hungary | 26 | 88 | 4/5 · 80.0% |
| Bulgaria | 21 | 112 | 3/4 · 75.0% |
For CTIS and EU submission planning, Germany and Spain create the broadest recurring country footprint, while Poland and France add the highest participant and site intensity. These are the countries where country-level start-up, site activation, and local coordination capacity are most relevant.
The most common outsourced function was central laboratory, bioanalysis, sample handling, or sample logistics, appearing in 12 of 30 trials, or 40.0%. IMP supply, packaging, storage, or destruction appeared in 7 trials, or 23.3%. Full-service CRO or clinical operations and eCOA, eDiary, or EDC systems each appeared in 6 trials, or 20.0%.
Rheumatoid arthritis outsourcing is not only about full-service trial management. The largest repeat need is specialist infrastructure: central labs, sample movement, bioanalysis, IMP logistics, and electronic clinical outcome capture.
The same dataset can answer which designs, indications, and operational profiles are most associated with CRO use. Design complexity was highly predictive: all 3 adaptive trials used CRO support, and 6 of 7 open-label trials used CRO support.
The best CRO-demand proxy is not phase alone. CRO need is strongest when phase 2 complexity combines with multi-country CTIS execution, higher participant burden, larger site networks, adaptive design, or subtype-defined RA populations.
CRO means contract research organization. CTIS means Clinical Trials Information System, the EU clinical trial submission and authorisation platform. IMP means investigational medicinal product. eCOA means electronic clinical outcome assessment. EDC means electronic data capture. PRO means patient-reported outcome. ICF means informed consent form.